Literature DB >> 28322975

A polymeric micelle magnetic resonance imaging (MRI) contrast agent reveals blood-brain barrier (BBB) permeability for macromolecules in cerebral ischemia-reperfusion injury.

Kouichi Shiraishi1, Zuojun Wang1, Daisuke Kokuryo2, Ichio Aoki2, Masayuki Yokoyama3.   

Abstract

Blood-brain barrier (BBB) opening is a key phenomenon for understanding ischemia-reperfusion injuries that are directly linked to hemorrhagic transformation. The recombinant human tissue-type plasminogen activator (rtPA) increases the risk of symptomatic intracranial hemorrhages. Recent imaging technologies have advanced our understanding of pathological BBB disorders; however, an ongoing challenge in the pre-"rtPA treatment" stage is the task of developing a rigorous method for hemorrhage-risk assessments. Therefore, we examined a novel method for assessment of rtPA-extravasation through a hyper-permeable BBB. To examine the image diagnosis of rtPA-extravasation for a rat transient occlusion-reperfusion model, in this study we used a polymeric micelle MRI contrast-agent (Gd-micelles). Specifically, we used two MRI contrast agents at 1h after reperfusion. Gd-micelles provided very clear contrast images in 15.5±10.3% of the ischemic hemisphere at 30min after i.v. injection, whereas a classic gadolinium chelate MRI contrast agent provided no satisfactorily clear images. The obtained images indicate both the hyper-permeable BBB area for macromolecules and the distribution area of macromolecules in the ischemic hemisphere. Owing to their large molecular weight, Gd-micelles remained in the ischemic hemisphere through the hyper-permeable BBB. Our results indicate the feasibility of a novel clinical diagnosis for evaluating rtPA-related hemorrhage risks.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  A polymeric micelle MRI contrast agent; Blood–brain barrier (BBB) permeability; Drug targeting; Focal ischemia-reperfusion injury; Magnetic resonance imaging (MRI)

Mesh:

Substances:

Year:  2017        PMID: 28322975     DOI: 10.1016/j.jconrel.2017.03.020

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  4 in total

Review 1.  Current Strategies to Enhance Delivery of Drugs across the Blood-Brain Barrier.

Authors:  Raluca Ioana Teleanu; Manuela Daniela Preda; Adelina-Gabriela Niculescu; Oana Vladâcenco; Crina Ioana Radu; Alexandru Mihai Grumezescu; Daniel Mihai Teleanu
Journal:  Pharmaceutics       Date:  2022-05-04       Impact factor: 6.525

Review 2.  Potential of Nanocarrier-Based Drug Delivery Systems for Brain Targeting: A Current Review of Literature.

Authors:  Badriyah Shadid Alotaibi; Manal Buabeid; Nihal Abdalla Ibrahim; Zelal Jaber Kharaba; Munazza Ijaz; Sobia Noreen; Ghulam Murtaza
Journal:  Int J Nanomedicine       Date:  2021-11-11

Review 3.  Current Strategies for Brain Drug Delivery.

Authors:  Xiaowei Dong
Journal:  Theranostics       Date:  2018-02-05       Impact factor: 11.556

Review 4.  Nanocarriers as Potential Drug Delivery Candidates for Overcoming the Blood-Brain Barrier: Challenges and Possibilities.

Authors:  Jyoti Ahlawat; Gileydis Guillama Barroso; Shima Masoudi Asil; Melinda Alvarado; Isabela Armendariz; Jose Bernal; Ximena Carabaza; Stephanie Chavez; Paulina Cruz; Vassti Escalante; Savana Estorga; Daniel Fernandez; Carolina Lozano; Martin Marrufo; Nabeel Ahmad; Sergio Negrete; Karyme Olvera; Ximena Parada; Brianna Portillo; Andrea Ramirez; Raul Ramos; Veronica Rodriguez; Paola Rojas; Jessica Romero; David Suarez; Graciela Urueta; Stephanie Viel; Mahesh Narayan
Journal:  ACS Omega       Date:  2020-06-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.